XORTX Total Assets from 2010 to 2024

XRTX Stock

USD 1.21 0.02 1.68%

XORTX Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 5 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2014-12-31

Previous Quarter

4.8 M

Current Value

3.9 M

Quarterly Volatility

6.1 M

Yuan Drop

Covid

Check XORTX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among XORTX Therapeutics' main balance sheet or income statement drivers, such as Selling General Administrative of 996.5 K, Other Operating Expenses of 2.6 M or Total Operating Expenses of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.89. XORTX financial statements analysis is a perfect complement when working with XORTX Therapeutics Valuation or Volatility modules.

Check out the analysis of XORTX Therapeutics Correlation against competitors.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Latest XORTX Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of XORTX Therapeutics over the last few years. Total assets refers to the total amount of XORTX Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in XORTX Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. XORTX Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 5.47 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

XORTX Total Assets Regression Statistics

	Arithmetic Mean	3,111,168
	Geometric Mean	875,298
	Coefficient Of Variation	165.04
	Mean Deviation	3,683,094
	Median	490,602
	Standard Deviation	5,134,606
	Sample Variance	26.4T
	Range	17.1M
	R-Value	0.63
	Mean Square Error	17T
	R-Squared	0.40
	Significance	0.01
	Slope	726,551
	Total Sum of Squares	369.1T

XORTX Total Assets History

	2024	5 M
	2023	5.5 M
	2022	12.3 M
	2021	17.3 M
	2020	2.3 M
	2019	1.1 M
	2018	1.3 M

Other Fundumenentals of XORTX Therapeutics

Intangibles To Total Assets

XORTX Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.98	-0.99	-0.5	0.53	0.76	0.89	1.0	-0.43	-0.74	0.91	0.56	-0.15	0.97	-0.62	1.0	0.84	0.73	0.92	-0.15	0.16
Total Stockholder Equity	0.98		-0.98	-0.49	0.39	0.71	0.8	0.98	-0.45	-0.75	0.92	0.56	-0.17	0.99	-0.58	0.99	0.83	0.73	0.93	-0.17	0.22
Net Debt	-0.99	-0.98		0.44	-0.51	-0.73	-0.88	-0.99	0.38	0.7	-0.89	-0.48	0.12	-0.97	0.54	-0.99	-0.79	-0.67	-0.89	0.12	-0.12
Retained Earnings	-0.5	-0.49	0.44		-0.36	-0.77	-0.37	-0.47	0.76	0.87	-0.76	-0.87	0.8	-0.48	0.78	-0.52	-0.85	-0.86	-0.74	0.8	-0.83
Accounts Payable	0.53	0.39	-0.51	-0.36		0.67	0.83	0.52	-0.23	-0.3	0.33	0.44	0.11	0.34	-0.56	0.49	0.53	0.35	0.37	0.11	-0.11
Net Receivables	0.76	0.71	-0.73	-0.77	0.67		0.74	0.74	-0.65	-0.78	0.78	0.77	-0.35	0.65	-0.72	0.75	0.9	0.75	0.81	-0.35	0.48
Total Liab	0.89	0.8	-0.88	-0.37	0.83	0.74		0.89	-0.27	-0.54	0.68	0.46	0.08	0.78	-0.57	0.86	0.71	0.56	0.71	0.08	-0.08
Total Current Assets	1.0	0.98	-0.99	-0.47	0.52	0.74	0.89		-0.42	-0.71	0.89	0.54	-0.13	0.97	-0.61	1.0	0.82	0.71	0.9	-0.13	0.13
Short Term Debt	-0.43	-0.45	0.38	0.76	-0.23	-0.65	-0.27	-0.42		0.58	-0.61	-0.84	0.56	-0.43	0.83	-0.46	-0.73	-0.67	-0.58	0.56	-0.56
Intangible Assets	-0.74	-0.75	0.7	0.87	-0.3	-0.78	-0.54	-0.71	0.58		-0.91	-0.71	0.65	-0.73	0.62	-0.75	-0.89	-0.95	-0.92	0.65	-0.71
Net Tangible Assets	0.91	0.92	-0.89	-0.76	0.33	0.78	0.68	0.89	-0.61	-0.91		0.7	-0.53	0.92	-0.68	0.93	0.91	0.87	0.98	-0.53	0.53
Long Term Debt	0.56	0.56	-0.48	-0.87	0.44	0.77	0.46	0.54	-0.84	-0.71	0.7		-0.48	0.54	-0.94	0.57	0.9	0.78	0.72	-0.48	0.65
Deferred Long Term Liab	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48		-0.21	0.41	-0.2	-0.44	-0.61	-0.44	1.0	-0.8
Net Invested Capital	0.97	0.99	-0.97	-0.48	0.34	0.65	0.78	0.97	-0.43	-0.73	0.92	0.54	-0.21		-0.58	0.98	0.81	0.71	0.92	-0.21	0.21
Short Long Term Debt	-0.62	-0.58	0.54	0.78	-0.56	-0.72	-0.57	-0.61	0.83	0.62	-0.68	-0.94	0.41	-0.58		-0.63	-0.86	-0.76	-0.67	0.41	-0.42
Net Working Capital	1.0	0.99	-0.99	-0.52	0.49	0.75	0.86	1.0	-0.46	-0.75	0.93	0.57	-0.2	0.98	-0.63		0.85	0.75	0.93	-0.2	0.19
Common Stock	0.84	0.83	-0.79	-0.85	0.53	0.9	0.71	0.82	-0.73	-0.89	0.91	0.9	-0.44	0.81	-0.86	0.85		0.9	0.94	-0.44	0.58
Property Plant Equipment	0.73	0.73	-0.67	-0.86	0.35	0.75	0.56	0.71	-0.67	-0.95	0.87	0.78	-0.61	0.71	-0.76	0.75	0.9		0.88	-0.61	0.6
Capital Stock	0.92	0.93	-0.89	-0.74	0.37	0.81	0.71	0.9	-0.58	-0.92	0.98	0.72	-0.44	0.92	-0.67	0.93	0.94	0.88		-0.44	0.54
Current Deferred Revenue	-0.15	-0.17	0.12	0.8	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48	1.0	-0.21	0.41	-0.2	-0.44	-0.61	-0.44		-0.8
Short Term Investments	0.16	0.22	-0.12	-0.83	-0.11	0.48	-0.08	0.13	-0.56	-0.71	0.53	0.65	-0.8	0.21	-0.42	0.19	0.58	0.6	0.54	-0.8

Click cells to compare fundamentals

About XORTX Therapeutics Financial Statements

XORTX Therapeutics investors use historical fundamental indicators, such as XORTX Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in XORTX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	5.5 M	5 M
Intangibles To Total Assets	0.03	0.03

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC